In financial papers (IBD and WSJ) as well as NY Times, I didn't see any coverage on the breast cancer prevention results (Tamoxifen is sold by ZEN). It's hard to see how this result could be a minus for LGND. They are involved with 2nd generation SERMs (Evista, Droloxifene, CP-366,156, and TSE424), all of which could be used in breast cancer prevention trials (as well as osteoporosis). The data on Tamoxifen sets the stage for new and improved versions (and there is much room for improvement), and I expect the above programs to accelerate, now that positive prevention data on Tamoxifen has been released.
In addition to the SERMs, LGND has a big lead in the area of Rexinoids, and the breast cancer prevention data should spur LLY on. Animal data indicates that Targretin is as good as Tamoxifen, but with fewer side effects (does not stimulate endometrial tissues). Moreover, Targretin synergizes with Tamoxifen AND is effective in treating the side effects (stimulation of endometrial tissues) associated with tamoxifen. Moreover, as shown in LGND's pipeline table (at home.att.net ), LGND has two 2nd generation rexinoids (LGD1268 and LGD1324) ready for IND filing, and it's likely that these compounds will be more effective than Targretin.
Future treatments of most diseases (as well as prevention) will rely on combinations of drugs, and LGND is well positioned in current and future drugs in the SERM and Rexinoid categories.
Before the open, LGND's bid has been raised. Ask remains at 16 1/4. |
